HTG Molecular Diagnostics unterbewertet? (Seite 93)
eröffnet am 24.11.20 11:43:26 von
neuester Beitrag 26.10.23 18:42:03 von
neuester Beitrag 26.10.23 18:42:03 von
Beiträge: 926
ID: 1.334.811
ID: 1.334.811
Aufrufe heute: 0
Gesamt: 40.172
Gesamt: 40.172
Aktive User: 0
ISIN: US40434H3021 · WKN: A3D39C
EUR
0,00 %
0,00 EUR
Letzter Kurs Lang & Schwarz
Neuigkeiten
| TitelBeiträge |
|---|
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,2500 | +50,00 | |
| 0,9899 | +41,41 | |
| 1,2900 | +35,79 | |
| 27,00 | +19,21 | |
| 0,8449 | +18,83 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5900 | -13,11 | |
| 0,8123 | -15,91 | |
| 7,3500 | -17,88 | |
| 1,7000 | -23,94 | |
| 0,8211 | -47,37 |
Beitrag zu dieser Diskussion schreiben
Feedback
Es hat begonnen. 3,78 Euro.🙊
Liest sich wie pure Poesie.🙂
Quelle
WEBPAGE HTG Molecular
TUCSON, Ariz., May 24, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that its HTG EdgeSeq technology is highlighted in several posters being presented at the American Society of Clinical Oncology (ASCO) conference, being held virtually from June 4-8, 2021.
“We are pleased to see our technology highlighted in so many abstracts at this year’s ASCO conference,” said Byron Lawson, Senior Vice President and Chief Commercial Officer. “It is very satisfying to see our partners and customers incorporating our HTG EdgeSeq technology into their research, and we look forward to building upon this momentum.”
Abstracts highlighting the use of HTG’s EdgeSeq technology at the ASCO conference include the following:
Abstract 506: Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Abstract 518: Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.
Abstract 519: Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.
Abstract 558: MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.
Abstract e14528: Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.
“We believe the number of posters highlighting our technology at this year’s ASCO conference further demonstrates the utility of our HTG EdgeSeq technology and how some of our customers are currently using it to further their research,” said John Lubniewski, President and CEO of HTG. “We are proud to partner with such innovative centers of science and believe that these abstracts, and the growing number of publications issued by our customers, will support our ability to grow our customer base and penetrate new markets for our HTG EdgeSeq technology.”
WEBPAGE HTG Molecular
TUCSON, Ariz., May 24, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that its HTG EdgeSeq technology is highlighted in several posters being presented at the American Society of Clinical Oncology (ASCO) conference, being held virtually from June 4-8, 2021.
“We are pleased to see our technology highlighted in so many abstracts at this year’s ASCO conference,” said Byron Lawson, Senior Vice President and Chief Commercial Officer. “It is very satisfying to see our partners and customers incorporating our HTG EdgeSeq technology into their research, and we look forward to building upon this momentum.”
Abstracts highlighting the use of HTG’s EdgeSeq technology at the ASCO conference include the following:
Abstract 506: Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Abstract 518: Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.
Abstract 519: Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.
Abstract 558: MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.
Abstract e14528: Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.
“We believe the number of posters highlighting our technology at this year’s ASCO conference further demonstrates the utility of our HTG EdgeSeq technology and how some of our customers are currently using it to further their research,” said John Lubniewski, President and CEO of HTG. “We are proud to partner with such innovative centers of science and believe that these abstracts, and the growing number of publications issued by our customers, will support our ability to grow our customer base and penetrate new markets for our HTG EdgeSeq technology.”
Trading Spotlight
Durchsuchen
